## Abstract Contrast kinetics were studied in the main pulmonary artery (MPA) and ascending aorta (AAo) of 12 children with congenital heart disease. This information was used to optimize the timing of data acquisition for contrast‐enhanced MR angiography in these vessels. To reduce contrast‐agent
Evaluation of radiofrequency pulses and contrast agent doses for use in 3D pulmonary magnetic resonance angiography
✍ Scribed by Sandra S. Halliburton; Cynthia B. Paschal; John D. Rothpletz
- Publisher
- John Wiley and Sons
- Year
- 1999
- Tongue
- English
- Weight
- 244 KB
- Volume
- 10
- Category
- Article
- ISSN
- 1053-1807
No coin nor oath required. For personal study only.
✦ Synopsis
Ten healthy volunteers were imaged with breath-hold, three-dimensional (3D) time-of-flight (TOF) magnetic resonance angiography (MRA) using single-variable-angle uniform signal excitation (VUSE), double-VUSE, and flat radiofrequency (RF) pulses with various doses of contrast agent. The ability of each technique to display pulmonary vasculature was evaluated. Images were segmented to isolate lungs, and maximum intensity projections (MIPs) were computed. All MIPs were assigned an image quality (IQ) rating, and signal-to-noise ratios (SNRs) were measured in pulmonary vessels. Without contrast agent, subsegmental vessels were displayed in single-and double-VUSE images while no vessels were visible in flat images. With equal doses of contrast agent, SNRs and IQ ratings were comparable for images obtained with VUSE and flat pulses. In addition, single-VUSE pulses produced more uniform signal from vessels than flat pulses in contrast-enhanced images. The results indicate that non-contrast-enhanced 3D TOF pulmonary MRA with VUSE RF pulses may be a useful screening tool. In addition, contrast-enhanced 3D TOF MRA with VUSE pulses may be useful as a stand-alone technique for assessing the pulmonary vasculature or as an adjunct to contrast-enhanced 3D TOF MRA with flat pulses.
📜 SIMILAR VOLUMES
## Abstract From May 2007 to January 2008, patients with Stage 3‐5 chronic kidney disease (CKD) undergoing gadobenate dimeglumine (GBD)‐enhanced magnetic resonance (MR) examinations were included in the retrospective investigation. The electronic medical records were reviewed to assess the prevalen